Oncology Companion Diagnostics Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
A companion diagnostic test is used to match a patient to a specific therapy or drug. An oncology companion diagnostic test identifies patient's genetic change or biomarker that is targeted by the drug.
MARKET SCOPE
The "Global Oncology Companion Diagnostics Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the oncology companion diagnostics market with detailed market segmentation by product, technology, disease type, end user, and geography. The report provides key statistics on the market status of the leading oncology companion diagnostics market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on product, the global oncology companion diagnostics market is segmented into instrument, consumable, and software.
- On the basis of technology, the market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), in situ hybridization (ISH)/fluorescence in situ hybridization (FISH), and other technologies.
- Based on disease type, the market is bifurcated into breast cancer, non-small cell lung cancer, colorectal cancer, leukemia, melanoma, prostate cancer, and others.
- On the basis of end user, the market is segmented into hospital, pathology/diagnostic laboratory, and academic medical center.
MARKET DYNAMICS
Drivers-
- Increasing number of FDA approvals for CDx assay.
- Rising prevalence of cancer.
- Benefits offered by oncology Companion Diagnostics (CDx) assays.
Restraints-
- High cost of cancer companion diagnostics tests
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The oncology companion diagnostics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Oncology companion diagnostics market in these regions.
IMPACT OF COVID-19 ON ONCOLOGY COMPANION DIAGNOSTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and medical industry in various countries due to lockdowns, travel bans, and business shutdowns. Various medical devices companies have shut down their productions, hence are unable to manufacture to meet the rising demand. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, COVID?19 pandemic caused damage in health care in terms of reduced hospital admissions or postponed treatment of patients suffering from other acute or chronic diseases. Further, In the United States, many doctors, hospitals and other healthcare facilities are delaying or canceling the cancer procedures, surgeries and sometimes screenings or other treatments, if it is not considered urgent, emergencies, or otherwise indicated for life-threatening conditions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The oncology companion diagnostics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Oncology companion diagnostics market in these regions.
IMPACT OF COVID-19 ON ONCOLOGY COMPANION DIAGNOSTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and medical industry in various countries due to lockdowns, travel bans, and business shutdowns. Various medical devices companies have shut down their productions, hence are unable to manufacture to meet the rising demand. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, COVID?19 pandemic caused damage in health care in terms of reduced hospital admissions or postponed treatment of patients suffering from other acute or chronic diseases. Further, In the United States, many doctors, hospitals and other healthcare facilities are delaying or canceling the cancer procedures, surgeries and sometimes screenings or other treatments, if it is not considered urgent, emergencies, or otherwise indicated for life-threatening conditions.
MARKET PLAYERS
The report covers key developments in the oncology companion diagnostics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from oncology companion diagnostics market are anticipated to lucrative growth opportunities in the future with the rising demand for oncology companion diagnostics in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the oncology companion diagnostics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Qiagen
- Illumina
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc
- Agilent Technologies, Inc.
- Arup Laboratories
- Abbott
- Myriad Genetics, Inc
- Biomérieux SA
- Invivoscribe
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oncology Companion Diagnostics Market - By Product
1.3.2 Oncology Companion Diagnostics Market - By Technology
1.3.3 Oncology Companion Diagnostics Market - By Disease Type
1.3.4 Oncology Companion Diagnostics Market - By End User
1.3.5 Oncology Companion Diagnostics Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ONCOLOGY COMPANION DIAGNOSTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ONCOLOGY COMPANION DIAGNOSTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ONCOLOGY COMPANION DIAGNOSTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. ONCOLOGY COMPANION DIAGNOSTICS - GLOBAL MARKET OVERVIEW
6.2. ONCOLOGY COMPANION DIAGNOSTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. INSTRUMENT
7.3.1. Overview
7.3.2. Instrument Market Forecast and Analysis
7.4. CONSUMABLE
7.4.1. Overview
7.4.2. Consumable Market Forecast and Analysis
7.5. SOFTWARE
7.5.1. Overview
7.5.2. Software Market Forecast and Analysis
8. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - TECHNOLOGY
8.1. OVERVIEW
8.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
8.3. POLYMERASE CHAIN REACTION (PCR)
8.3.1. Overview
8.3.2. Polymerase Chain Reaction (PCR) Market Forecast and Analysis
8.4. NEXT-GENERATION SEQUENCING (NGS)
8.4.1. Overview
8.4.2. Next-Generation Sequencing (NGS) Market Forecast and Analysis
8.5. IMMUNOHISTOCHEMISTRY (IHC)
8.5.1. Overview
8.5.2. Immunohistochemistry (IHC) Market Forecast and Analysis
8.6. IN SITU HYBRIDIZATION (ISH)/FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
8.6.1. Overview
8.6.2. In Situ Hybridization (ISH)/Fluorescence in Situ Hybridization (FISH) Market Forecast and Analysis
8.7. OTHER TECHNOLOGIES
8.7.1. Overview
8.7.2. Other Technologies Market Forecast and Analysis
9. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
9.1. OVERVIEW
9.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
9.3. BREAST CANCER
9.3.1. Overview
9.3.2. Breast Cancer Market Forecast and Analysis
9.4. NON-SMALL CELL LUNG CANCER
9.4.1. Overview
9.4.2. Non-Small Cell Lung Cancer Market Forecast and Analysis
9.5. COLORECTAL CANCER
9.5.1. Overview
9.5.2. Colorectal Cancer Market Forecast and Analysis
9.6. LEUKEMIA
9.6.1. Overview
9.6.2. Leukemia Market Forecast and Analysis
9.7. MELANOMA
9.7.1. Overview
9.7.2. Melanoma Market Forecast and Analysis
9.8. PROSTATE CANCER
9.8.1. Overview
9.8.2. Prostate Cancer Market Forecast and Analysis
9.9. OTHERS
9.9.1. Overview
9.9.2. Others Market Forecast and Analysis
10. ONCOLOGY COMPANION DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITAL
10.3.1. Overview
10.3.2. Hospital Market Forecast and Analysis
10.4. PATHOLOGY/DIAGNOSTIC LABORATORY
10.4.1. Overview
10.4.2. Pathology/Diagnostic Laboratory Market Forecast and Analysis
10.5. ACADEMIC MEDICAL CENTER
10.5.1. Overview
10.5.2. Academic Medical Center Market Forecast and Analysis
11. ONCOLOGY COMPANION DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Oncology Companion Diagnostics Market Overview
11.1.2 North America Oncology Companion Diagnostics Market Forecasts and Analysis
11.1.3 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.1.4 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.1.5 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.1.6 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.1.7 North America Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.1.7.1 United States Oncology Companion Diagnostics Market
11.1.7.1.1 United States Oncology Companion Diagnostics Market by Product
11.1.7.1.2 United States Oncology Companion Diagnostics Market by Technology
11.1.7.1.3 United States Oncology Companion Diagnostics Market by Disease Type
11.1.7.1.4 United States Oncology Companion Diagnostics Market by End User
11.1.7.2 Canada Oncology Companion Diagnostics Market
11.1.7.2.1 Canada Oncology Companion Diagnostics Market by Product
11.1.7.2.2 Canada Oncology Companion Diagnostics Market by Technology
11.1.7.2.3 Canada Oncology Companion Diagnostics Market by Disease Type
11.1.7.2.4 Canada Oncology Companion Diagnostics Market by End User
11.1.7.3 Mexico Oncology Companion Diagnostics Market
11.1.7.3.1 Mexico Oncology Companion Diagnostics Market by Product
11.1.7.3.2 Mexico Oncology Companion Diagnostics Market by Technology
11.1.7.3.3 Mexico Oncology Companion Diagnostics Market by Disease Type
11.1.7.3.4 Mexico Oncology Companion Diagnostics Market by End User
11.2. EUROPE
11.2.1 Europe Oncology Companion Diagnostics Market Overview
11.2.2 Europe Oncology Companion Diagnostics Market Forecasts and Analysis
11.2.3 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.2.4 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.2.5 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.2.6 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.2.7 Europe Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Oncology Companion Diagnostics Market
11.2.7.1.1 Germany Oncology Companion Diagnostics Market by Product
11.2.7.1.2 Germany Oncology Companion Diagnostics Market by Technology
11.2.7.1.3 Germany Oncology Companion Diagnostics Market by Disease Type
11.2.7.1.4 Germany Oncology Companion Diagnostics Market by End User
11.2.7.2 France Oncology Companion Diagnostics Market
11.2.7.2.1 France Oncology Companion Diagnostics Market by Product
11.2.7.2.2 France Oncology Companion Diagnostics Market by Technology
11.2.7.2.3 France Oncology Companion Diagnostics Market by Disease Type
11.2.7.2.4 France Oncology Companion Diagnostics Market by End User
11.2.7.3 Italy Oncology Companion Diagnostics Market
11.2.7.3.1 Italy Oncology Companion Diagnostics Market by Product
11.2.7.3.2 Italy Oncology Companion Diagnostics Market by Technology
11.2.7.3.3 Italy Oncology Companion Diagnostics Market by Disease Type
11.2.7.3.4 Italy Oncology Companion Diagnostics Market by End User
11.2.7.4 Spain Oncology Companion Diagnostics Market
11.2.7.4.1 Spain Oncology Companion Diagnostics Market by Product
11.2.7.4.2 Spain Oncology Companion Diagnostics Market by Technology
11.2.7.4.3 Spain Oncology Companion Diagnostics Market by Disease Type
11.2.7.4.4 Spain Oncology Companion Diagnostics Market by End User
11.2.7.5 United Kingdom Oncology Companion Diagnostics Market
11.2.7.5.1 United Kingdom Oncology Companion Diagnostics Market by Product
11.2.7.5.2 United Kingdom Oncology Companion Diagnostics Market by Technology
11.2.7.5.3 United Kingdom Oncology Companion Diagnostics Market by Disease Type
11.2.7.5.4 United Kingdom Oncology Companion Diagnostics Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Oncology Companion Diagnostics Market Overview
11.3.2 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis
11.3.3 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.3.4 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.3.5 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.3.6 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Oncology Companion Diagnostics Market
11.3.7.1.1 Australia Oncology Companion Diagnostics Market by Product
11.3.7.1.2 Australia Oncology Companion Diagnostics Market by Technology
11.3.7.1.3 Australia Oncology Companion Diagnostics Market by Disease Type
11.3.7.1.4 Australia Oncology Companion Diagnostics Market by End User
11.3.7.2 China Oncology Companion Diagnostics Market
11.3.7.2.1 China Oncology Companion Diagnostics Market by Product
11.3.7.2.2 China Oncology Companion Diagnostics Market by Technology
11.3.7.2.3 China Oncology Companion Diagnostics Market by Disease Type
11.3.7.2.4 China Oncology Companion Diagnostics Market by End User
11.3.7.3 India Oncology Companion Diagnostics Market
11.3.7.3.1 India Oncology Companion Diagnostics Market by Product
11.3.7.3.2 India Oncology Companion Diagnostics Market by Technology
11.3.7.3.3 India Oncology Companion Diagnostics Market by Disease Type
11.3.7.3.4 India Oncology Companion Diagnostics Market by End User
11.3.7.4 Japan Oncology Companion Diagnostics Market
11.3.7.4.1 Japan Oncology Companion Diagnostics Market by Product
11.3.7.4.2 Japan Oncology Companion Diagnostics Market by Technology
11.3.7.4.3 Japan Oncology Companion Diagnostics Market by Disease Type
11.3.7.4.4 Japan Oncology Companion Diagnostics Market by End User
11.3.7.5 South Korea Oncology Companion Diagnostics Market
11.3.7.5.1 South Korea Oncology Companion Diagnostics Market by Product
11.3.7.5.2 South Korea Oncology Companion Diagnostics Market by Technology
11.3.7.5.3 South Korea Oncology Companion Diagnostics Market by Disease Type
11.3.7.5.4 South Korea Oncology Companion Diagnostics Market by End User
11.3.7.6 Rest of Asia-Pacific Oncology Companion Diagnostics Market
11.3.7.6.1 Rest of Asia-Pacific Oncology Companion Diagnostics Market by Product
11.3.7.6.2 Rest of Asia-Pacific Oncology Companion Diagnostics Market by Technology
11.3.7.6.3 Rest of Asia-Pacific Oncology Companion Diagnostics Market by Disease Type
11.3.7.6.4 Rest of Asia-Pacific Oncology Companion Diagnostics Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Oncology Companion Diagnostics Market Overview
11.4.2 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis
11.4.3 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.4.4 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.4.5 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.4.6 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Oncology Companion Diagnostics Market
11.4.7.1.1 South Africa Oncology Companion Diagnostics Market by Product
11.4.7.1.2 South Africa Oncology Companion Diagnostics Market by Technology
11.4.7.1.3 South Africa Oncology Companion Diagnostics Market by Disease Type
11.4.7.1.4 South Africa Oncology Companion Diagnostics Market by End User
11.4.7.2 Saudi Arabia Oncology Companion Diagnostics Market
11.4.7.2.1 Saudi Arabia Oncology Companion Diagnostics Market by Product
11.4.7.2.2 Saudi Arabia Oncology Companion Diagnostics Market by Technology
11.4.7.2.3 Saudi Arabia Oncology Companion Diagnostics Market by Disease Type
11.4.7.2.4 Saudi Arabia Oncology Companion Diagnostics Market by End User
11.4.7.3 U.A.E Oncology Companion Diagnostics Market
11.4.7.3.1 U.A.E Oncology Companion Diagnostics Market by Product
11.4.7.3.2 U.A.E Oncology Companion Diagnostics Market by Technology
11.4.7.3.3 U.A.E Oncology Companion Diagnostics Market by Disease Type
11.4.7.3.4 U.A.E Oncology Companion Diagnostics Market by End User
11.4.7.4 Rest of Middle East and Africa Oncology Companion Diagnostics Market
11.4.7.4.1 Rest of Middle East and Africa Oncology Companion Diagnostics Market by Product
11.4.7.4.2 Rest of Middle East and Africa Oncology Companion Diagnostics Market by Technology
11.4.7.4.3 Rest of Middle East and Africa Oncology Companion Diagnostics Market by Disease Type
11.4.7.4.4 Rest of Middle East and Africa Oncology Companion Diagnostics Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Oncology Companion Diagnostics Market Overview
11.5.2 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis
11.5.3 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Product
11.5.4 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Technology
11.5.5 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Disease Type
11.5.6 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By End User
11.5.7 South and Central America Oncology Companion Diagnostics Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Oncology Companion Diagnostics Market
11.5.7.1.1 Brazil Oncology Companion Diagnostics Market by Product
11.5.7.1.2 Brazil Oncology Companion Diagnostics Market by Technology
11.5.7.1.3 Brazil Oncology Companion Diagnostics Market by Disease Type
11.5.7.1.4 Brazil Oncology Companion Diagnostics Market by End User
11.5.7.2 Argentina Oncology Companion Diagnostics Market
11.5.7.2.1 Argentina Oncology Companion Diagnostics Market by Product
11.5.7.2.2 Argentina Oncology Companion Diagnostics Market by Technology
11.5.7.2.3 Argentina Oncology Companion Diagnostics Market by Disease Type
11.5.7.2.4 Argentina Oncology Companion Diagnostics Market by End User
11.5.7.3 Rest of South and Central America Oncology Companion Diagnostics Market
11.5.7.3.1 Rest of South and Central America Oncology Companion Diagnostics Market by Product
11.5.7.3.2 Rest of South and Central America Oncology Companion Diagnostics Market by Technology
11.5.7.3.3 Rest of South and Central America Oncology Companion Diagnostics Market by Disease Type
11.5.7.3.4 Rest of South and Central America Oncology Companion Diagnostics Market by End User
12. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ONCOLOGY COMPANION DIAGNOSTICS MARKET
12.1 North America
12.2 Europe
12.3 Asia-Pacific
12.4 Middle East and Africa
12.5 South and Central America
13. INDUSTRY LANDSCAPE
13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
14. ONCOLOGY COMPANION DIAGNOSTICS MARKET, KEY COMPANY PROFILES
14.1. QIAGEN
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. ILLUMINA, INC.
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. F. HOFFMANN-LA ROCHE LTD.
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. THERMO FISHER SCIENTIFIC, INC.
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. AGILENT TECHNOLOGIES, INC.
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. ARUP LABORATORIES
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. ABBOTT
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. MYRIAD GENETICS, INC
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. BIOMéRIEUX SA
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments
14.10. INVIVOSCRIBE, INC.
14.10.1. Key Facts
14.10.2. Business Description
14.10.3. Products and Services
14.10.4. Financial Overview
14.10.5. SWOT Analysis
14.10.6. Key Developments
15. APPENDIX
15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS
* Above given report scope is tentative, and may change during the study process as per the research requirement.
* List of companies provided under ‘Company Profile’ chapter is tentative and may change during the course of the study. This list is customizable as per the client requirements.
* Financial information would be provided only for the public companies.
1. Qiagen
2. Illumina
3. F. Hoffmann-La Roche Ltd.
4. Thermo Fisher Scientific, Inc
5. Agilent Technologies, Inc.
6. Arup Laboratories
7. Abbott
8. Myriad Genetics, Inc
9. Biomérieux SA
10. Invivoscribe
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For